C4 Therapeutics, Inc. Shareholders' Equity
C4 Therapeutics, Inc. (CCCC) had Shareholders' Equity of $247.26 million as of 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Balance Sheet › Equity › Equity, Attributable to Parent
us-gaap:StockholdersEquity · last filed 2026-08-11
- 2026-06-30: Stockholders' Equity Attributable to Parent $247.26M.
- 2026-03-31: Stockholders' Equity Attributable to Parent $234.25M.
- 2025-12-31: Stockholders' Equity Attributable to Parent $256.59M.
- 2025-09-30: Stockholders' Equity Attributable to Parent $154.41M.
| Period end | Stockholders' Equity Attributable to Parent | Stockholders' Equity Attributable to Parent as first filed |
|---|---|---|
| 2026-06-30 | $247.26M 10-Q · filed 2026-08-11 | |
| 2026-03-31 | $234.25M 10-Q · filed 2026-08-11 | |
| 2025-12-31 | $256.59M 10-Q · filed 2026-08-11 | |
| 2025-09-30 | $154.41M 10-Q · filed 2025-11-06 | |
| 2025-06-30 | $174.06M 10-Q · filed 2026-08-11 | |
| 2025-03-31 | $195.14M 10-Q · filed 2026-08-11 | |
| 2024-12-31 | $215.99M 10-Q · filed 2026-08-11 | |
| 2024-09-30 | $242.66M 10-Q · filed 2025-11-06 | |
| 2024-06-30 | $247.06M 10-Q · filed 2025-11-06 | |
| 2024-03-31 | $258.28M 10-Q · filed 2025-11-06 | |
| 2023-12-31 | $246.11M 10-K · filed 2026-02-26 | |
| 2023-09-30 | $216.02M 10-Q · filed 2024-10-31 | |
| 2023-06-30 | $233.71M 10-Q · filed 2024-10-31 | |
| 2023-03-31 | $262.47M 10-Q · filed 2024-10-31 | |
| 2022-12-31 | $289.23M 10-K · filed 2025-02-27 | |
| 2022-09-30 | $318.18M 10-Q · filed 2023-11-01 | |
| 2022-06-30 | $344.59M 10-Q · filed 2023-11-01 | |
| 2022-03-31 | $364.53M 10-Q · filed 2023-11-01 | |
| 2021-12-31 | $389.61M 10-K · filed 2024-02-22 | |
| 2021-09-30 | $398.78M 10-Q · filed 2022-11-03 | |
| 2021-06-30 | $416.43M 10-Q · filed 2022-11-03 | |
| 2021-03-31 | $263.70M 10-Q · filed 2022-11-03 | |
| 2020-12-31 | $280.79M 10-K · filed 2023-02-23 | |
| 2020-09-30 | -$155.92M 10-Q · filed 2021-11-10 | |
| 2020-06-30 | -$135.06M 10-Q · filed 2021-11-10 | -$135.06M 10-Q · filed 2020-11-12 |
| 2020-03-31 | -$124.53M 10-Q · filed 2021-11-10 | -$124.53M 10-Q · filed 2021-05-13 |
| 2019-12-31 | -$111.96M 10-K · filed 2022-02-24 | |
| 2019-09-30 | -$102.67M 10-Q · filed 2020-11-12 | |
| 2019-06-30 | -$93.41M 10-Q · filed 2020-11-12 | |
| 2018-12-31 | -$79.75M 10-K · filed 2022-02-24 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| FENNEC PHARMACEUTICALS INC. (FENC) | United States | $0.371B | -115.85 |
| Artiva Biotherapeutics, Inc. (ARTV) | United States | $0.367B | |
| Cabaletta Bio, Inc. (CABA) | United States | $0.365B | -2.81 |
| AGENUS INC (AGEN) | United States | $0.383B | 1.41 |
| Surrozen, Inc./DE (SRZN) | United States | $0.395B | |
| Zura Bio Ltd (ZURA) | $0.398B | -6.56 | |
| Ocugen, Inc. (OCGN) | United States | $0.343B | -6.34 |
| Scribe Therapeutics, Inc. (SCTX) | United States | $0.410B | |
| Editas Medicine, Inc. (EDIT) | United States | $0.424B | -4.29 |
| Kyverna Therapeutics, Inc. (KYTX) | United States | $0.434B | -3.60 |